AZ-Daiichi, Astellas, Prevnar rival and more—FiercePharmaAsia by Angus Liu Friday, January 3, 2020 Daiichi and AZ's Enhertu as well as and Astellas and Seattle Genetics' Padcev won FDA nods as China approved rivals to Prevnar and Gardasil.
China approves rivals to Pfizer, Merck cash cow vaccines by Angus Liu Thursday, January 2, 2020 Chinese drug regulators approved two domestically made vaccines, rivals to Pfizer's Prevnar 13 and Merck's and GSK's HPV shots.
Merck siphons CDC supplies again as Gardasil global sales surge by Eric Palmer Wednesday, October 30, 2019 Merck & Co. won’t be able to fully meet global demand for HPV vaccine Gardasil until after 2023 when it completes two manufacturing plants.
Social Media: 'Versed on HPV' by Beth Snyder Bulik Young people may be versed when it comes to music, fashion and pop culture, but they're far from knowledgeable about the risks of HPV. Almost half of the 14 million new HPV infections in the U.S. are among people ages 15-24.
Growth of Gardasil 9 leads Merck to expand production again by Eric Palmer Friday, July 26, 2019 Merck's expansion of Gardasil production in Virginia and now in North Carolina means $1.68 billion in investments and 525 new jobs.
Merck's Gardasil blockbuster sales prompt $1B plant expansion by Eric Palmer Wednesday, May 8, 2019 Merck & Co., which has been riding a wave of Gardasil sales, will invest $1 billion and add 100 jobs to expand production.
Keytruda's 'wall of data' bodes well for Merck growth by Angus Liu Tuesday, April 30, 2019 Keytruda grew sales by 60% at constant currencies, boosting its share in Merck's portfolio. Could China and a few new indications step on the gas?
Mom speaks up in Merck's latest HPV awareness push by Beth Snyder Bulik Wednesday, March 20, 2019 Merck continues its HPV awareness campaign with a twist. In new TV, a parent is the narrator for the first time in the three-year-old campaign.
Merck analysts to CEO Frazier: What’s so great about the pipeline? by Arlene Weintraub Friday, February 1, 2019 Merck's 2019 sales expectations are on the low side of what analysts expected, intensifying concerns about growth beyond I-O star Keytruda.
Merck hikes prices on Keytruda, Gardasil and more by Eric Sagonowsky Thursday, November 29, 2018 Among small batch of price increases for the pharma giant was a 1.5% increase on superstar cancer drug Keytruda and 6% on HPV shot Gardasil.
